Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

NextCure, Inc. Director's Dealing 2019

May 9, 2019

35069_dirs_2019-05-08_191109aa-0722-40fc-a6c2-e91435729a28.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: NextCure, Inc. (NXTC)
CIK: 0001661059
Period of Report: 2019-05-08

Reporting Person: Alexandria Venture Investments, LLC (10% Owner)

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Series A-1 Preferred Stock $ Common Stock (27819.0) Direct
Series A-2 Preferred Stock $ Common Stock (46366.0) Direct
Series A-3 Preferred Stock $ Common Stock (45523.0) Direct
Series B-1 Preferred Stock $ Common Stock (78285.0) Direct

Footnotes

F1: The preferred stock is convertible into the Issuer's common stock at a ratio of 8.0338 shares of preferred stock to 1 share of common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering, for no additional consideration.

F2: Not applicable